Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.

Slifka MK, Amanna IJ.

Front Immunol. 2019 May 1;10:956. doi: 10.3389/fimmu.2019.00956. eCollection 2019. Review.

2.

An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults.

Woods CW, Sanchez AM, Swamy GK, McClain MT, Harrington L, Freeman D, Poore EA, Slifka DK, Poer DeRaad DE, Amanna IJ, Slifka MK, Cai S, Shahamatdar V, Wierzbicki MR, Amegashie C, Walter EB.

Vaccine. 2019 Jan 18. pii: S0264-410X(18)31699-2. doi: 10.1016/j.vaccine.2018.12.026. [Epub ahead of print]

3.

Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Quintel BK, Thomas A, Poer DeRaad DE, Slifka MK, Amanna IJ.

Vaccine. 2018 Dec 31. pii: S0264-410X(18)31691-8. doi: 10.1016/j.vaccine.2018.12.020. [Epub ahead of print]

PMID:
30606462
4.

Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE Jr, Slifka MK, Fremont DH, Klimstra WB, Diamond MS.

Nat Microbiol. 2019 Jan;4(1):187-197. doi: 10.1038/s41564-018-0286-4. Epub 2018 Nov 19.

5.

Dengue Serostatus and Dengue Vaccine Safety and Efficacy.

Slifka MK, Amanna IJ.

N Engl J Med. 2018 Nov 15;379(20):1968. doi: 10.1056/NEJMc1811986. No abstract available.

PMID:
30439281
6.

Successful Vaccines.

Amanna IJ, Slifka MK.

Curr Top Microbiol Immunol. 2018 Jul 26. doi: 10.1007/82_2018_102. [Epub ahead of print]

PMID:
30046984
7.

Plasma cell survival in the absence of B cell memory.

Hammarlund E, Thomas A, Amanna IJ, Holden LA, Slayden OD, Park B, Gao L, Slifka MK.

Nat Commun. 2017 Nov 24;8(1):1781. doi: 10.1038/s41467-017-01901-w.

8.

Lymphatic Vessels Balance Viral Dissemination and Immune Activation following Cutaneous Viral Infection.

Loo CP, Nelson NA, Lane RS, Booth JL, Loprinzi Hardin SC, Thomas A, Slifka MK, Nolz JC, Lund AW.

Cell Rep. 2017 Sep 26;20(13):3176-3187. doi: 10.1016/j.celrep.2017.09.006.

9.

T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, Robb ML, Ostrowski MA, Deeks SG, Slifka MK, Tomaras GD, Moir S, Moody MA, Betts MR.

JCI Insight. 2017 Apr 20;2(8). pii: 92943. doi: 10.1172/jci.insight.92943. eCollection 2017 Apr 20.

10.

Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine.

Poore EA, Slifka DK, Raué HP, Thomas A, Hammarlund E, Quintel BK, Torrey LL, Slifka AM, Richner JM, Dubois ME, Johnson LP, Diamond MS, Slifka MK, Amanna IJ.

Vaccine. 2017 Jan 5;35(2):283-292. doi: 10.1016/j.vaccine.2016.11.080. Epub 2016 Dec 3.

11.

Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.

Laws LH, Parker CE, Cherala G, Koguchi Y, Waisman A, Slifka MK, Oberbarnscheidt MH, Obhrai JS, Yeung MY, Riella LV.

Am J Transplant. 2016 Nov;16(11):3139-3149. doi: 10.1111/ajt.13902. Epub 2016 Jul 12.

12.

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.

Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE Jr.

Cell. 2016 Oct 20;167(3):684-694.e9. doi: 10.1016/j.cell.2016.09.049.

13.

Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection.

Demers KR, Makedonas G, Buggert M, Eller MA, Ratcliffe SJ, Goonetilleke N, Li CK, Eller LA, Rono K, Maganga L, Nitayaphan S, Kibuuka H, Routy JP, Slifka MK, Haynes BF, McMichael AJ, Bernard NF, Robb ML, Betts MR.

PLoS Pathog. 2016 Aug 3;12(8):e1005805. doi: 10.1371/journal.ppat.1005805. eCollection 2016 Aug.

14.

Alcohol intake alters immune responses and promotes CNS viral persistence in mice.

Loftis JM, Taylor J, Raué HP, Slifka MK, Huang E.

Behav Brain Res. 2016 Oct 1;312:1-8. doi: 10.1016/j.bbr.2016.06.006. Epub 2016 Jun 4.

15.

Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Amanna IJ, Slifka MK.

Expert Rev Vaccines. 2016 Dec;15(12):1519-1533. Epub 2016 Jun 20. Review.

16.

Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis.

Hammarlund E, Thomas A, Poore EA, Amanna IJ, Rynko AE, Mori M, Chen Z, Slifka MK.

Clin Infect Dis. 2016 May 1;62(9):1111-1118. doi: 10.1093/cid/ciw066. Epub 2016 Mar 21. Erratum in: Clin Infect Dis. 2016 Jul 1;63(1):150.

17.

Cytokine-Mediated Activation of NK Cells during Viral Infection.

Freeman BE, Raué HP, Hill AB, Slifka MK.

J Virol. 2015 Aug;89(15):7922-31. doi: 10.1128/JVI.00199-15. Epub 2015 May 20.

18.

Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model.

Engelmann F, Josset L, Girke T, Park B, Barron A, Dewane J, Hammarlund E, Lewis A, Axthelm MK, Slifka MK, Messaoudi I.

PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3295. doi: 10.1371/journal.pntd.0003295. eCollection 2014.

19.

Vaccine-mediated immunity against dengue and the potential for long-term protection against disease.

Slifka MK.

Front Immunol. 2014 May 6;5:195. doi: 10.3389/fimmu.2014.00195. eCollection 2014. Review.

20.

T cell inactivation by poxviral B22 family proteins increases viral virulence.

Alzhanova D, Hammarlund E, Reed J, Meermeier E, Rawlings S, Ray CA, Edwards DM, Bimber B, Legasse A, Planer S, Sprague J, Axthelm MK, Pickup DJ, Lewinsohn DM, Gold MC, Wong SW, Sacha JB, Slifka MK, Früh K.

PLoS Pathog. 2014 May 15;10(5):e1004123. doi: 10.1371/journal.ppat.1004123. eCollection 2014 May.

21.

Anti-inflammatory cytokines directly inhibit innate but not adaptive CD8+ T cell functions.

Freeman BE, Meyer C, Slifka MK.

J Virol. 2014 Jul;88(13):7474-84. doi: 10.1128/JVI.00658-14. Epub 2014 Apr 16.

22.

How advances in immunology provide insight into improving vaccine efficacy.

Slifka MK, Amanna I.

Vaccine. 2014 May 23;32(25):2948-57. doi: 10.1016/j.vaccine.2014.03.078. Epub 2014 Apr 5. Review.

23.

Current trends in West Nile virus vaccine development.

Amanna IJ, Slifka MK.

Expert Rev Vaccines. 2014 May;13(5):589-608. doi: 10.1586/14760584.2014.906309. Epub 2014 Apr 1. Review.

24.

Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis.

Slifka MK, Leung DY, Hammarlund E, Raué HP, Simpson EL, Tofte S, Baig-Lewis S, David G, Lynn H, Woolson R, Hata T, Milgrom H, Hanifin J.

J Allergy Clin Immunol. 2014 Feb;133(2):439-47. doi: 10.1016/j.jaci.2013.10.037. Epub 2013 Dec 10.

25.

A cell-intrinsic requirement for NF-κB-inducing kinase in CD4 and CD8 T cell memory.

Rowe AM, Murray SE, Raué HP, Koguchi Y, Slifka MK, Parker DC.

J Immunol. 2013 Oct 1;191(7):3663-72. doi: 10.4049/jimmunol.1301328. Epub 2013 Sep 4.

26.

Editorial: Profiling senescent influenza-specific T cells in the elderly.

Messaoudi I, Slifka MK.

J Leukoc Biol. 2013 Jun;93(6):819-21. doi: 10.1189/jlb.0313149. No abstract available.

PMID:
23723376
27.

Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG.

Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ.

Transplantation. 2013 May 15;95(9):e59-61. doi: 10.1097/TP.0b013e31828c6d9e. No abstract available.

28.

Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells.

Raué HP, Beadling C, Haun J, Slifka MK.

Immunity. 2013 Jan 24;38(1):131-9. doi: 10.1016/j.immuni.2012.09.019. Epub 2012 Dec 20.

29.

A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, Diamond MS.

J Virol. 2013 Feb;87(4):1926-36. doi: 10.1128/JVI.02903-12. Epub 2012 Dec 5.

30.

Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Walker JM, Raué HP, Slifka MK.

J Virol. 2012 Dec;86(24):13735-44. doi: 10.1128/JVI.02178-12. Epub 2012 Oct 10.

31.

A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus.

Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F, Messaoudi I, Slifka MK.

PLoS One. 2012;7(9):e41707. doi: 10.1371/journal.pone.0041707. Epub 2012 Sep 19.

32.

Impact of infection or vaccination on pre-existing serological memory.

Amanna IJ, Hammarlund E, Lewis MW, Slifka MK.

Hum Immunol. 2012 Nov;73(11):1082-6. doi: 10.1016/j.humimm.2012.07.328. Epub 2012 Aug 16.

33.

Regulation of innate CD8+ T-cell activation mediated by cytokines.

Freeman BE, Hammarlund E, Raué HP, Slifka MK.

Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9971-6. doi: 10.1073/pnas.1203543109. Epub 2012 Jun 4.

34.

Development of a new hydrogen peroxide–based vaccine platform.

Amanna IJ, Raué HP, Slifka MK.

Nat Med. 2012 Jun;18(6):974-9. doi: 10.1038/nm.2763.

35.

Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8- thymocytes and invariant NKT cells but not in Treg cells.

Koguchi Y, Buenafe AC, Thauland TJ, Gardell JL, Bivins-Smith ER, Jacoby DB, Slifka MK, Parker DC.

PLoS One. 2012;7(2):e31296. doi: 10.1371/journal.pone.0031296. Epub 2012 Feb 21.

36.

Optimization of peptide-based ELISA for serological diagnostics: a retrospective study of human monkeypox infection.

Dubois ME, Hammarlund E, Slifka MK.

Vector Borne Zoonotic Dis. 2012 May;12(5):400-9. doi: 10.1089/vbz.2011.0779. Epub 2012 Jan 4.

37.

GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.

Judkowski V, Bunying A, Ge F, Appel JR, Law K, Sharma A, Raja-Gabaglia C, Norori P, Santos RG, Giulianotti MA, Slifka MK, Douek DC, Graham BS, Pinilla C.

PLoS One. 2011;6(9):e24091. doi: 10.1371/journal.pone.0024091. Epub 2011 Sep 9.

38.

Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Früh K.

J Virol. 2011 Oct;85(19):10154-66. doi: 10.1128/JVI.05298-11. Epub 2011 Jul 27.

39.

Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis.

De Benedetto A, Slifka MK, Rafaels NM, Kuo IH, Georas SN, Boguniewicz M, Hata T, Schneider LC, Hanifin JM, Gallo RL, Johnson DC, Barnes KC, Leung DY, Beck LA.

J Allergy Clin Immunol. 2011 Jul;128(1):242-246.e5. doi: 10.1016/j.jaci.2011.02.014. Epub 2011 Apr 13. No abstract available. Erratum in: J Allergy Clin Immunol. 2011 Oct; 128(4):903.

40.

Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Amanna IJ, Slifka MK.

Virology. 2011 Mar 15;411(2):206-15. doi: 10.1016/j.virol.2010.12.016. Epub 2011 Jan 8. Review.

41.

Antiviral immunity following smallpox virus infection: a case-control study.

Hammarlund E, Lewis MW, Hanifin JM, Mori M, Koudelka CW, Slifka MK.

J Virol. 2010 Dec;84(24):12754-60. doi: 10.1128/JVI.01763-10. Epub 2010 Oct 6.

42.

Longevity of T-cell memory following acute viral infection.

Walker JM, Slifka MK.

Adv Exp Med Biol. 2010;684:96-107. Review.

PMID:
20795543
43.

Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

Amanna IJ, Slifka MK.

Immunol Rev. 2010 Jul;236:125-38. doi: 10.1111/j.1600-065X.2010.00912.x. Review. Erratum in: Immunol Rev. 2010 Sep;237(1):284.

PMID:
20636813
44.

Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition.

Alzhanova D, Edwards DM, Hammarlund E, Scholz IG, Horst D, Wagner MJ, Upton C, Wiertz EJ, Slifka MK, Früh K.

Cell Host Microbe. 2009 Nov 19;6(5):433-45. doi: 10.1016/j.chom.2009.09.013.

45.

Wanted, dead or alive: new viral vaccines.

Amanna IJ, Slifka MK.

Antiviral Res. 2009 Nov;84(2):119-30. doi: 10.1016/j.antiviral.2009.08.008. Epub 2009 Sep 4. Review.

46.

Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue.

O'Rourke RW, Metcalf MD, White AE, Madala A, Winters BR, Maizlin II, Jobe BA, Roberts CT Jr, Slifka MK, Marks DL.

Int J Obes (Lond). 2009 Sep;33(9):978-90. doi: 10.1038/ijo.2009.133. Epub 2009 Jun 30.

47.

CD8+ T cell immunodominance shifts during the early stages of acute LCMV infection independently from functional avidity maturation.

Raué HP, Slifka MK.

Virology. 2009 Aug 1;390(2):197-204. doi: 10.1016/j.virol.2009.05.021. Epub 2009 Jun 18.

48.

Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation.

Hammarlund E, Dasgupta A, Pinilla C, Norori P, Früh K, Slifka MK.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14567-72. doi: 10.1073/pnas.0800589105. Epub 2008 Sep 16.

49.

The immunostimulatory power of acute viral infection.

Walker JM, Slifka MK.

Immunity. 2008 May;28(5):604-6. doi: 10.1016/j.immuni.2008.04.009.

50.

Serologic evidence for novel poxvirus in endangered red Colobus monkeys, Western Uganda.

Goldberg TL, Chapman CA, Cameron K, Saj T, Karesh WB, Wolfe ND, Wong SW, Dubois ME, Slifka MK.

Emerg Infect Dis. 2008 May;14(5):801-3. doi: 10.3201/eid1405.071686.

Supplemental Content

Loading ...
Support Center